NantOmics Revenue and Competitors
Estimated Revenue & Valuation
- NantOmics's estimated annual revenue is currently $930k per year.
- NantOmics's estimated revenue per employee is $155,000
Employee Data
- NantOmics has 6 Employees.
- NantOmics grew their employee count by -14% last year.
NantOmics's People
Name | Title | Email/Phone |
---|---|---|
1 | CEO & Founder | Reveal Email/Phone |
2 | Chief Scientific Officer | Reveal Email/Phone |
3 | Medical Director | Reveal Email/Phone |
4 | President Proteomics | Reveal Email/Phone |
5 | President Genomics | Reveal Email/Phone |
NantOmics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is NantOmics?
NantOmics, LLC is a biotechnology company based out of 9920 Jefferson Street, Culver City, California, United States.
keywords:N/AN/A
Total Funding
6
Number of Employees
$930k
Revenue (est)
-14%
Employee Growth %
N/A
Valuation
N/A
Accelerator
NantOmics News
2022-04-20 - Brain Cancer Diagnostics Market Analysis Worldwide Growth ...
Biocept Inc., Canon Medical Systems Corporation, GE Healthcare, Hitachi Ltd., Koninklijke Philips N.V., NantOmics LLC, Neusoft Medical...
2022-03-22 - Brain Cancer Diagnostics Market Research Insights: 2022 ...
Biocept Inc., Canon Medical Systems Corporation, GE Healthcare, Hitachi Ltd., Koninklijke Philips N.V., NantOmics LLC, Neusoft Medical...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $0.4M | 6 | 0% | N/A |
#2 | $0.4M | 6 | -14% | N/A |
#3 | $75M | 6 | 0% | N/A |
#4 | $0.4M | 6 | 0% | N/A |
#5 | $0.4M | 6 | -14% | N/A |